Oseltamivir INN, marketed under the trade name Tamiflu, is an antiviral drug, which may slow the spread of influenza (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell. The drug is taken orally in capsules or as a suspension. It is used to treat influenza A virus and influenza B virus. Oseltamivir is a prodrug, a (relatively) inactive chemical, which is converted into its active form by metabolic process after it is taken into the body. It was the first orally active neuraminidase inhibitor commercially developed. It was developed by C.U. Kim, W. Lew, and X. Chen of US-based Gilead Sciences, and is marketed by Genentech. Some have reported that the median time to symptom alleviation is reduced by 0.51 day. There have been questions about its efficacy as the company that manufactures it (Roche) has refused to release the trial data for independent analysis.
Contributions by Pigkeeper, Techelf, and Shaddack.